

compounds affecting such activity. Assaying lethal factor activity can be used to better characterize and study such activity and to obtain lethal factor inhibitory compounds.

Detailed Description Text (40):

With appropriately labeled substrates alternate technologies can be used to measure substrate cleavage. Examples of homogeneous formats would include fluorescence polarization, time resolved FRET, SPA.TM., FlashPlate.TM., and AlphaScreen.TM.. Examples of heterogeneous formats would include DELFIA.TM., chemiluminescence plate based assays, HPLC, radioactive filter binding assays, absorbance assays, and fluorescence assays.

Detailed Description Text (42):

Lethal factor substrates can be used in methods measuring Bacillus anthracis lethal factor activity and the effect of a compound on such activity. Such methods involve incubating a lethal factor substrate described herein with Bacillus anthracis lethal factor using an incubation medium where the Bacillus anthracis lethal factor is active, and can include the presence of a compound being tested. Cleavage of the substrate can be detected as a measure of Bacillus anthracis lethal factor activity or the effect of a compound on lethal factor activity. Measuring can be qualitative or quantitative.

Other Reference Publication (1):

Park, S. et al. "Optimized Production and Purification of Bacillus anthracis Lethal Factor", Protein Expression and Purification, 2000, vol. 18, pp. 293-302.

Other Reference Publication (3):

Cummings, R. et al. "A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease", Proc. Natl. Acad. Sci. USA, 2002, vol. 99, pp. 6603-6606. *

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L4: Entry 2 of 3

File: USPT

Oct 18, 2005

DOCUMENT-IDENTIFIER: US 6955891 B2

**** See image for Certificate of Correction ****TITLE: Reagents for assaying Bacillus anthracis lethal factor proteaseAbstract Text (1):

The present invention features a Bacillus anthracis lethal factor substrate. The substrate can be used for example to measure lethal factor activity. Preferred substrates contain one or more detectable labels and have a sufficiently high turnover rate for applications in a high throughput screen.

Brief Summary Text (3):

Anthrax is a bacterial infection produced by Bacillus anthracis. Bacillus anthracis endospores can enter the body through skin abrasions, inhalation, or ingestion. Bacillus anthracis produces an anthrax toxin that is often lethal. (Dixon et al., (1999) N. Engl. J. Med. 341, 815-26.)

Brief Summary Text (4):

Anthrax toxin consists of three proteins, a receptor-binding component designated protective antigen, and two enzymatic components termed edema factor and lethal factor ("LF"). (Mock et al., (2001) Annu. Rev. Microbiol. 55, 647-71.) Lethal factor is a zinc-dependent metalloprotease that appears to exert toxic effects by cleaving mitogen-activated protein kinase kinases (MKKs). (Vitale et al., (1998) Biochem. Biophys. Res. Commun. 248, 706-11, Vitale et al., (2000) Biochem. J. 352 Pt 3, 739-45, Duesbery et al., (1998) Science 280, 734-7, Duesbery et al., International Publication No. WO 99/50439, International Publication Date Oct. 7, 1999.)

Brief Summary Text (8):

The present invention features a Bacillus anthracis lethal factor substrate and assays employing the substrate to measure lethal factor activity and to screen for compounds affecting lethal factor activity. Preferred substrates contain one or more detectable labels and have a sufficiently high turnover rate to be suitable for use in a high throughput screen.

Brief Summary Text (14):

Another aspect of the present invention features a method of measuring Bacillus anthracis lethal factor activity. The method comprises the steps of: (a) incubating lethal factor and a lethal factor substrate using an incubation medium wherein the lethal factor is active; and (b) measuring cleavage of the peptide.

Brief Summary Text (15):

Another aspect of the present invention features a method of measuring the ability of a compound to affect Bacillus anthracis lethal factor activity. The method comprises the steps of: (a) incubating the compound, lethal factor, and a lethal factor substrate using an incubation medium wherein the lethal factor is active; and (b) measuring cleavage of the peptide.

Detailed Description Text (2):

The present invention features a Bacillus anthracis lethal factor substrate and assays employing the substrate to measure lethal factor activity and to screen for

Refine Search

Search Results -

Terms	Documents
L3 and protective adj antigen	3

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L4

Search History

DATE: Tuesday, September 11, 2007

[Purge Queries](#)[Printable Copy](#)[Create Case](#)**Set Name Query**

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=AND

<u>L4</u>	L3 and protective adj antigen	3	<u>L4</u>
<u>L3</u>	L2 and anthracis	106	<u>L3</u>
<u>L2</u>	L1 and bacillus	368	<u>L2</u>
<u>L1</u>	fluorescence adj polarization	1946	<u>L1</u>

END OF SEARCH HISTORY

Hit List

First Hit

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 7183105 B2

L4: Entry 1 of 3

File: USPT

Feb 27, 2007

US-PAT-NO: 7183105

DOCUMENT-IDENTIFIER: US 7183105 B2

TITLE: Eubacterial minicells and their use as vectors for nucleic acid delivery and expression

DATE-ISSUED: February 27, 2007

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20030199088 A1

October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sabbadini; Roger A.	Lakeside	CA		US
Berkley; Neil	San Diego	CA		US
Surber; Mark W.	Coronado	CA		US

US-CL-CURRENT: 435/320.1; 424/93.1, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Abstracts	Claims	KWIC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-----------	--------	------	---------

☐ 2. Document ID: US 6955891 B2

L4: Entry 2 of 3

File: USPT

Oct 18, 2005

US-PAT-NO: 6955891

DOCUMENT-IDENTIFIER: US 6955891 B2

**** See image for Certificate of Correction ****TITLE: Reagents for assaying Bacillus anthracis lethal factor protease

DATE-ISSUED: October 18, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cunningham; Barry R.	Scotch Plains	NJ		
Cummings; Richard T.	Fanwood	NJ		

Hermes; Jeffrey D. Warren NJ
Salowe; Scott Dayton NJ

US-CL-CURRENT: [435/34](#); [435/4](#), [530/300](#), [530/324](#), [530/325](#), [530/326](#), [530/806](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Similarity	Attachments	Claims	RIMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	------------	-------------	--------	------	---------

☐ 3. Document ID: US 6927068 B2

L4: Entry 3 of 3

File: USPT

Aug 9, 2005

US-PAT-NO: 6927068

DOCUMENT-IDENTIFIER: US 6927068 B2

TITLE: Rapid and non-invasive method to evaluate immunization status of a patient

DATE-ISSUED: August 9, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Simonson; Lloyd G.	Spring Grove	IL		
Kelly; John R.	Rockville	MD		

US-CL-CURRENT: [436/518](#); [422/56](#), [422/57](#), [422/58](#), [422/59](#), [422/60](#), [435/252.31](#),
[435/7.1](#), [435/7.93](#), [435/7.94](#), [435/970](#), [436/514](#), [436/517](#), [436/528](#), [436/530](#), [436/541](#),
[436/810](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Similarity	Attachments	Claims	RIMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	------------	-------------	--------	------	---------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

L3 and protective adj antigen

3

Display Format: CIT

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

>No matching display code(s) found in file(s): 65, 135, 158, 342,
390-391, 764

9/3,AB/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142426380 CA: 142(23)426380y PATENT
Fluorescence polarization instruments and methods for detection of
exposure to biological materials by fluorescence polarization immunoassay
of saliva, oral or bodily fluids
INVENTOR(AUTHOR): Cullum, Malford E.; Simonson, Lloyd G.; Schade, Sylvia
Z.; Lininger, Linda A.; McArthur, Alan L.
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20050095601 A1 DATE: 20050505
APPLICATION: US 2003700868 (20031105)
PAGES: 18 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435006000; C12Q-001/68A; G01N-033/53B

9/3,AB/2 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142019550 CA: 142(2)19550b PATENT
Rapid competitive fluorescence-polarization immunoassay of anthrax
protective antigen in vaccine cultures and bodily fluids
INVENTOR(AUTHOR): Cullum, Malford E.; Hine, Paul; Simonson, Lloyd G.;
Shih, Chun N.; Bienek, Diane R.; Park, Sukjoon; Ragain, James C.
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20040235075 A1 DATE: 20041125
APPLICATION: US 2004809877 (20040326) *US 2003PV457940 (20030328)
PAGES: 10 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007320; G01N-033/554A; G01N-033/569B

?

after
filing

hogene dans une cellule ou un organisme. Le domaine de detection de pathogene et le domaine effecteur des molecules chimeriques sont des domaines qui, en general, ne sont pas naturellement associes. L'invention concerne egalement des agents comprenant au moins une structure moleculaire interagissant avec un pathogene et au moins une structure moleculaire a mediation d'effecteur, ledit agent n'apparaissant pas naturellement dans une cellule. Les methodes de prevention et de traitement decrites sont efficaces pour un large spectre de pathogenes, et presentent peu d'effets secondaires ou pas d'effets toxiques. L'invention concerne egalement des dosages permettant la detection d'un pathogene, d'un composant pathogene ou d'un produit produit ou induit par un pathogene.

? ds

Set	Items	Description
S1	53323	BACILLUS (1W) ANTHRACIS
S2	7143	S1 AND PROTECTIVE (1W) ANTIGEN
S3	1574	S2 AND ASSAY
S4	1	S3 AND DETECTING (1W) PROTECTIVE (1W) ANTIGEN

? s s4 and detect? (1w) protective (1w) antigen

Processing

Processing

>>>File 349 processing for DETECT? stopped at DETECTIONTABLE

Processed 10 of 60 files ...

Processing

Processed 20 of 60 files ...

Processing

Completed processing all files

	1	S4
	17194234	DETECT?
	2535765	PROTECTIVE
	3316912	ANTIGEN
	60	DETECT?(1W)PROTECTIVE(1W)ANTIGEN
S5	1	S4 AND DETECT? (1W) PROTECTIVE (1W) ANTIGEN

?

>Records from unsupported files will be retained in the RD set.

S7 56 RD (unique items)
? s s7 and fluorescence (1w) polarization

56 S7
2286511 FLUORESCENCE
1361633 POLARIZATION
52314 FLUORESCENCE(1W)POLARIZATION

S8 5 S7 AND FLUORESCENCE (1W) POLARIZATION

? t s8/3,ab/1-5

>>>No matching display code(s) found in file(s): 65, 135, 158, 342,
390-391, 764

8/3,AB/1 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

144463810 CA: 144(25)463810a PATENT
Method for the detection of stress biomarkers including cortisol by
fluorescence polarization
INVENTOR(AUTHOR): Cullum, Malford E.; Duplessis, Christopher A.; Crepeau,
Loring J.

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20060105397 A1 DATE: 20060518

APPLICATION: US 2006328486 (20060104) *US 2003700868 (20031105)

PAGES: 11 pp., Cont.-in-part of U.S. Ser. No. 700,868. CODEN: USXXCO

LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 435007100

IPCR/8 + Level Value Position Status Version Action Source Office:

G01N-0033/53 A I F B 20060101 20060518 H US

8/3,AB/2 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

144019192 CA: 144(2)19192c PATENT
Hand-held fluorescence polarimeter
INVENTOR(AUTHOR): Cullum, Malford E.; Naday, Istvan; McArthur, Alan L.
LOCATION: USA

ASSIGNEE: U.S. Government

PATENT: U.S. Pat. Appl. Publ. ; US 20050272145 A1 DATE: 20051208

APPLICATION: US 2005148572 (20050602) *US 2003700868 (20031105)

PAGES: 7 pp., Cont.-in-part of U.S. Ser. No. 700,868. CODEN: USXXCO

LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 435287200; C12M-001/34A; G01J-003/42B; G01N-033/542B

8/3,AB/3 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142426380 CA: 142(23)426380y PATENT
Fluorescence polarization instruments and methods for detection of
exposure to biological materials by fluorescence polarization immunoassay
of saliva, oral or bodily fluids

INVENTOR(AUTHOR): Cullum, Malford E.; Simonson, Lloyd G.; Schade, Sylvia
Z.; Lininger, Linda A.; McArthur, Alan L.

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20050095601 A1 DATE: 20050505

APPLICATION: US 2003700868 (20031105)

PAGES: 18 pp. CODEN: USXXCO LANGUAGE: English

PATENT CLASSIFICATIONS:

Cullum

2006

X

CLASS: 435006000; C12Q-001/68A; G01N-033/53B

8/3,AB/4 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142019550 CA: 142(2)19550b PATENT
Rapid competitive fluorescence-polarization immunoassay of anthrax
protective antigen in vaccine cultures and bodily fluids
INVENTOR(AUTHOR): Cullum, Malford E.; Hine, Paul; Simonson, Lloyd G.;
Shih, Chun N.; Bienek, Diane R.; Park, Sukjoon; Ragain, James C.
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20040235075 A1 DATE: 20041125
APPLICATION: US 2004809877 (20040326) *US 2003PV457940 (20030328)
PAGES: 10 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007320; G01N-033/554A; G01N-033/569B

8/3,AB/5 (Item 1 from file: 8)
DIALOG(R)File 8:EI Compendex(R)
(c) 2007 Elsevier Eng. Info. Inc. All rts. reserv.

10695770
E.I. No: EIP05459461750
Title: Biomonitoring of physiological status and cognitive performance of
underway submariners undergoing a novel watch-standing schedule
Author: Duplessis, C.A.; ***Cullum, M.E.*** ; Crepeau, L.J.
Corporate Source: Naval Submarine Medical Research Laboratory (NSMRL) Box
900, Groton, CT 06349, United States
Conference Title: Biomonitoring for Physiological and Cognitive
Performance during Military Operations
Conference Location: Orlando, FL, United States Conference Date:
20050331-20050401
E.I. Conference No.: 65889
Source: Proceedings of SPIE - The International Society for Optical
Engineering Biomonitoring for Physiological and Cognitive Performance
during Military Operations v 5797 2005.
Publication Year: 2005
CODEN: PSISDG ISSN: 0277-786X
Language: English
Abstract: Submarine watch-standers adhere to a 6 hour-on, 12 hour-off
(6/12) watch-standing schedule, yoking them to an 18-hr day, engendering
circadian desynchronization and chronic sleep deprivation. Moreover, the
chronic social crowding, shift work, and confinement of submarine life
provide additional stressors known to correlate with elevated secretory
immunoglobulin A (slgA) and cortisol levels, reduced performance,
immunologic dysfunction, malignancies, infections, gastrointestinal
illness, coronary disease, anxiety, and depression. We evaluated an
alternative, compressed, fixed work schedule designed to enhance circadian
rhythm entrainment, sleep hygiene, performance, and health on 10 underway
submariners, who followed the alternative and 6/12 schedules for
approximately 2 weeks each. We measured subjects' sleep, cognitive
performance, and salivary biomarker levels. Pilot analysis of the salivary
data on one subject utilizing ELISA suggests elevated biomarker levels of
stress. Average PM cortisol levels were 0.2 mug/L (normal range:
nondetectable - 0.15 mug/L), and mean slgA levels were 562 mug/ml (normal
range: 100-500 mug/ml). Future research exploiting real-time salivary
bioassays, via fluorescent polarimetry technology, identified by the
Office of Naval Research (ONR) as a future Naval requirement, allows
researchers to address correlations between stress-induced elaboration of
salivary biomarkers with physiological and performance decrements, thereby
fostering insight into the underway submariner's psychoimmunological

status. This may help identify strategies that enhance resilience to stressors. Specifically, empirically-based modeling can identify optimal watch-standing schedules and stress-mitigating procedures - within the operational constraints of the submarine milieu and the mission - that foster improved circadian entrainment and reduced stress reactivity, enhancing physiological health, operational performance, safety, and job satisfaction. 27 Refs.

?

>>>Duplicate detection is not supported for File 342.

>>>Records from unsupported files will be retained in the RD set.

>>>Record 440:21419672 incomplete bibliographic data - record retained in RD set

S5 48 RD (unique items)

? ds

Set	Items	Description
S1	52314	FLUORESCENCE (1W) POLARIZATION
S2	435	S1 AND BACILLUS (1W) ANTHRACIS
S3	435	S2 AND POLARIZATION
S4	49	S3 AND PROTECTIVE (1W) ANTIGEN
S5	48	RD (unique items)

? t s5/3,ab/1-48

>>>No matching display code(s) found in file(s): 65, 135, 158, 342, 390-391, 764

5/3,AB/1 (Item 1 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

7200410

UTILITY

Integrase-dirived HIV-inhibiting agents

Inventor: Yao, Xiaojian, Winnipeg, CA

Ao, Zhu-jun, Winnipeg, CA

Assignee: Unassigned

Correspondence Address: SMART & BIGGAR;P.O. BOX 2999, STATION D, 900-55
METCALFE STREET, OTTAWA, ON, K1P5Y6, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20070203325	A1	20070830	US 2006606904	20061201
Provisional				US 60-776202	20060224

Fulltext Word Count: 26123

Abstract:

[00000] The present invention relates to agents based on integrase of HIV-1, for inhibiting the proliferation of HIV-1. The agents are derived from the C-terminal domain of HIV-1 integrase, comprising at least one of the regions identified as being important for interaction between integrase and imp7 or imp[small beta, Greek], and/or for nuclear localization of the HIV PIC, replication of HIV, or infection of HIV.

5/3,AB/2 (Item 2 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

7075322

UTILITY

Rhamnose-inducible expression systems and methods

Inventor: Surber, Mark W., Coronado, CA, US

Assignee: Unassigned

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET,
FOURTEENTH FLOOR, IRVINE, CA, 92614, US

Publication Number	Kind	Date	Application Number	Filing Date

*Chris Day
Summer 2011 - Sep 11
Pat-pat/pat/chr
#33*

Main Patent	US 20070122881	A1	20070531	US 2006580095	20061011
Division	US 7183105			US 2002156902	20020528
Division	ABANDONED			US 2002154951	20020524
Provisional				US 60-293566	20010524
Provisional				US 60-359843	20020225

Fulltext Word Count: 141444

Abstract:

[00000] Rhamnose-inducible expression constructs are described. The expression constructs may be either episomal or chromosomal and may include at least one rhamnose-inducible regulatory element expressing a regulatory protein and at least one promoter that is inducible by the regulatory protein. An open reading frame expressing a protein of interest may be placed under control of the promoter. Also described are optimized Shine-Dalgarno sequences for use with the promoter.

5/3,AB/3 (Item 3 from file: 654)
 DIALOG(R)File 654:US PAT.FULL.
 (c) Format only 2007 Dialog. All rts. reserv.

6947956

UTILITY

Eubacterial minicells and their use as vectors for nucleic acid delivery and expression

Inventor: Sabbadini, Roger A., Lakeside, CA, US
 Berkley, Neil, San Diego, CA, US
 Surber, Mark W., Coronado, CA, US

Assignee: Vaxiion Therapeutics, Inc., (02), San Diego, CA, US

Examiner: Woitach, Joseph

Assistant Examiner: Kelly, Robert M.

Legal Representative: Knobbe, Martens, Olson & Bear, LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 7183105	B2	20070227	US 2002156902	20020528
Related Publ	US 20030199088	A1	20031023		
Division	ABANDONED			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 139244

Abstract:

[00000] Th invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/4 (Item 4 from file: 654)
 DIALOG(R)File 654:US PAT.FULL.
 (c) Format only 2007 Dialog. All rts. reserv.

6633407

Derwent Accession: 2004-543536

UTILITY

High-sensitivity assays for pathogen detection using metal enhanced fluorescence

Inventor: Geddes, Chris D., Baltimore, MD, US
 Lakowitz, Joseph R., Ellicott City, MD, US

Baillie, Leslie W.J., Columbia, MD, US
Assignee: Unassigned
Correspondence Address: MOORE & VAN ALLEN PLLC, P.O. BOX 13706, Research
Triangle Park, NC, 27709, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20060147927	A1	20060706	US 2003536502	20031126
PCT	WO 2003US38163		20031126		
Provisional				US 60-429263	20021126

Fulltext Word Count: 15160

Abstract:

[00000] The present invention relates to an assay including a surface having silver colloids or islands attached thereto. Attached to the surface and/or silver colloids/islands are polynucleotides which are complementary to a target polynucleotide sequence. The assay is performed by adding the target polynucleotide sequence to the assay surface and allowed to hybridize with the capture polynucleotides. Fluorophore-labeled capture polynucleotides are added and hybridize to the target polynucleotide. Bound target polynucleotides are detected by metal enhanced fluorescence.

5/3,AB/5 (Item 5 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

6293414

Derwent Accession: 2003-731625

UTILITY

Reagents for assaying Bacillus anthracis lethal factor protease

Inventor: Cunningham, Barry R., Scotch Plains, NJ, US

Cummings, Richard T., Fanwood, NJ, US

Hermes, Jeffrey D., Warren, NJ, US

Salowe, Scott, Dayton, NJ, US

Assignee: Merck & Co., Inc., (02), Rahway, NJ, US

Examiner: Gitomer, Ralph

Assistant Examiner: Srivastava, Kailash C.

Legal Representative: Heber, Sheldon O.; Tribble, Jack L.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6955891	B2	20051018	US 2003424954	20030428
Related Publ	US 20040019182	A1	20040129		
Continuation	PENDING			WO 2003US5553	20030221
Provisional				US 60-359707	20020225

US Term Extension: 10 days

Fulltext Word Count: 6506

Abstract:

[00000] The present invention features a Bacillus anthracis lethal factor substrate. The substrate can be used for example to measure lethal factor activity. Preferred substrates contain one or more detectable labels and have a sufficiently high turnover rate for applications in a high throughput screen.

5/3,AB/6 (Item 6 from file: 654)

DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

6087009

Derwent Accession: 2005-345008

UTILITY

Fluorescence polarization instruments and methods for detection
of exposure to biological materials by fluorescence
polarization immunoassay of saliva, oral or bodily fluids

Inventor: Cullum, Malford E., Grayslake, IL, US
Simonson, Lloyd G., Spring Grove, IL, US
Schade, Sylvia Z., Riverside, IL, US
Lininger, Linda A., Grayslake, IL, US
McArthur, Alan L., Mokena, IL, US

Assignee: Unassigned

Correspondence Address: NAVAL MEDICAL RESEARCH CENTER;Office of Counsel
(Code 00L), 503 Robert Grant Avenue, Silver Spring, MD, 20910-7500, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20050095601	A1	20050505	US 2003700868	20031105

Fulltext Word Count: 11314

Abstract:

[00000] The inventive subject matter relates to a method for detecting the presence of a biological substance of interest in a test sample of saliva or oral fluid, comprising combining said test sample with a fluorescence-labeled ligand to said biological substance and detecting a change in the fluorescence polarization of said test sample produced by binding of said fluorescence-labeled ligand to said biological substance. In one aspect of the inventive subject matter, said method comprises additional steps for comparing the fluorescence polarization of said test sample with the fluorescence

polarization of a control solution. Also provided is a miniaturized, portable apparatus for measuring the fluorescence.
polarization of a liquid sample.

5/3,AB/7 (Item 7 from file: 654)

DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005886085

Derwent Accession: 2004-832947

Rapid immunoassay of anthrax protective antigen in vaccine cultures and bodily fluids by fluorescence polarization

Inventor: Cullum, Malford, INV
Hine, Paul, INV
Simonson, Lloyd, INV
Shih, Chun, INV
Bienek, Diane, INV
Park, Sukjoon, INV
Ragain, James, INV

Correspondence Address: NAVAL MEDICAL RESEARCH CENTER ATTN: (CODE 00L), 503
ROBERT GRANT AVENUE, SILVER SPRING, MD, 20910-7500, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20040235075	A1	20041125	US 2004809877	20040326
Provisional				US 60-457940	20030328

Fulltext Word Count: 9069

Abstract:

The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a Bacillus anthracis protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of ***Fluorescence***, ***Polarization***, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0.1 to 10.0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including B. anthracis by fluorescent methods.

5/3,AB/8 (Item 8 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005517599

Derwent Accession: 2003-731625

Reagents and methods for assaying Bacillus anthracis lethal factor protease

Inventor: Cunningham, Barry, INV
Cummings, Richard, INV
Hermes, Jeffrey, INV
Salowe, Scott, INV

Correspondence Address: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ,
070650907

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040019182	A1	20040129	US 2003424954	20030428
Continuation	PENDING			WO 2003US5552	20030221
Provisional				US 60-359707	20020225

Fulltext Word Count: 7106

Abstract:

The present invention features a Bacillus anthracis lethal factor substrate and assays employing the substrate to measure lethal factor activity and to screen for compounds affecting lethal factor activity. Preferred substrates contain one or more detectable labels and have a sufficiently high turnover rate to be suitable for use in a high throughput screen.

5/3,AB/9 (Item 9 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005494132

Derwent Accession: 2004-090101

Poroplasts

Inventor: Surber, Mark, INV
Giacalone, Matthew, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040005700	A1	20040108	US 2002157339	20020528

Fulltext Word Count: 139104

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/10 (Item 10 from file: 654)
 DIALOG(R)File 654:US PAT.FULL.
 (c) Format only 2007 Dialog. All rts. reserv.

0005472936

Derwent Accession: 2004-052155

Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins

Inventor: Surber, Mark, INV

Berkley, Neil, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030232335	A1	20031218	US 2002157317	20020528
Provisional				US 60-359843	20020225

Fulltext Word Count: 139758

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/11 (Item 11 from file: 654)
 DIALOG(R)File 654:US PAT.FULL.
 (c) Format only 2007 Dialog. All rts. reserv.

0005457043

Derwent Accession: 2004-033964

Antibodies to native conformations of membrane proteins

Inventor: Sabbadini, Roger, INV

Berkley, Neil, INV

Surber, Mark, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

Publication Number	Kind	Date	Application Number	Filing Date
-----	--	-----	-----	-----

Main Patent US 20030224444 A1 20031204 US 2002157491 20020528
Provisional US 60-359843 20020225

Fulltext Word Count: 139621

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/12 (Item 12 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005456968

Derwent Accession: 2004-060537

Reverse screening and target identification with minicells

Inventor: Surber, Mark, INV

Berkley, Neil, INV

Gerhart, William, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030224369	A1	20031204	US 2002157171	20020528
Provisional				US 60-359843	20020225

Fulltext Word Count: 140274

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/13 (Item 13 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005448426

Derwent Accession: 2004-060193

Minicell-based bioremediation

Inventor: Segall, Anca, INV

Klepper, Robert, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030219888	A1	20031127	US 2002157418	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225

Fulltext Word Count: 141008

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/14 (Item 14 from file: 654)
 DIALOG(R)File 654:US PAT.FULL.
 (c) Format only 2007 Dialog. All rts. reserv.

0005448290

Derwent Accession: 2004-021946

Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Inventor: Short, Jay, INV

Assignee: Diversa Corporation(02), San Diego, CA, 92121, US, 4955 Directors Place

Correspondence Address: FISH & RICHARDSON, PC, 4350 LA JOLLA VILLAGE DRIVE SUITE 500, SAN DIEGO, CA, 92122, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030219752	A1	20031127	US 2002151469	20020517
Division	PENDING			US 2000687219	20001012
Division	US 6174673			US 9898206	19980616
Division	PENDING			US 2000636778	20000811
Continuation	US 6335179			US 98185373	19981103
Continuation	US 5830696			US 96760489	19961205
Continuation	US 6171820			US 99246178	19990204
Continuation	US 6335179			US 98185373	19981103
Continuation	US 5965408			US 96677112	19960709
Continuation	US 6174673			US 9898206	19980616
Continuation	US 6174673			US 9898206	19980616
CIP	US 6361974			US 2000535754	20000327
CIP	US 6358709			US 2000522289	20000309
CIP	ABANDONED			US 2000498557	20000204
CIP	US 6479258			US 2000495052	20000131
CIP	US 6352842			US 99276860	19990326
CIP	US 6238884			US 99267118	19990309
CIP	US 6171820			US 99246178	19990204
CIP	US 5965408			US 96677112	19960709
CIP	PENDING			WO 2000US16838	20000614
CIP	PENDING			WO 2000US8245	20000327
CIP	PENDING			WO 2000US6497	20000309
CIP	PENDING			US 2000594459	20000614
CIP	US 6537776			US 99332835	19990614
CIP	PENDING			WO 2000US3086	20000204
CIP	PENDING			US 2001756459	20010108
CIP	US 5830696			US 96760489	19961205
CIP	US 6440668			US 99376727	19990817
CIP	PENDING			WO 98US22596	19981023
CIP	PENDING			US 99214645	19990927
CIP	PENDING			US 2001790321	20010221
CIP	PENDING			US 2000636778	20000811

CIP	US 6468724	US 2001876276	20010607
CIP	PENDING	US 2001761559	20010116
CIP	PENDING	US 97876276	19970616
CIP	PENDING	US 2001848185	20010503
CIP	PENDING	US 97876276	19970616
CIP	PENDING	US 2000738871	20001215
CIP	PENDING	US 2000685432	20001010
CIP	PENDING	US 99444112	19991122
CIP	US 6174673	US 9898206	19980616
CIP	PENDING	US 97876276	19970616
CIP	PENDING	WO 2000US32208	20001122
CIP	PENDING	WO 98US12674	19980616
PCT	WO 97US12239	19970709	
Provisional		US 60-300381	20010517
Provisional		US 60-300907	20010625
Provisional		US 60-8311	19951207
Provisional		US 60-8316	19951207
Provisional		US 60-8311	19951207

Fulltext Word Count: 197101

Abstract:

The invention is directed to methods for generating sets, or libraries, of nucleic acids encoding antigen-binding sites, such as antibodies, antibody domains or other fragments, including single and double stranded antibodies, major histocompatibility complex (MHC) molecules, T cell receptors (TCRs), and the like. This invention provides methods for generating variant antigen binding sites, e.g., antibodies and specific domains or fragments of antibodies (e.g., Fab or Fc domains), by altering template nucleic acids including by saturation mutagenesis, synthetic ligation reassembly, or a combination thereof. In one aspect, invention provides methods for generating all human or humanized antibodies and evolving them to achieve optimized properties related to stability, duration, expression, production, enzymatic activity, affinity, avidity, localization, and other immunological properties. Polypeptides generated by these methods can be analyzed using a novel capillary array platform, which provides unprecedented ultra-high throughput screening.

5/3,AB/15 (Item 15 from file: 654)
 DIALOG(R)File 654:US PAT.FULL.
 (c) Format only 2007 Dialog. All rts. reserv.

0005447946

Derwent Accession: 2004-051708

Methods of making pharmaceutical compositions with minicells

Inventor: Sabbadini, Roger, INV

Klepper, Robert, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
 STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030219408	A1	20031127	US 2002157320	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 141223

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/16 (Item 16 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005432040

Derwent Accession: 2003-901592

Minicell-based delivery agents

Inventor: Sabbadini, Roger, INV

Klepper, Robert, INV

Surber, Mark, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030211599	A1	20031113	US 2002157106	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 141219

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/17 (Item 17 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005431528

Derwent Accession: 2004-051566

Minicell-based selective absorption

Inventor: Berkley, Neil, INV

Sabbadini, Roger, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030211086	A1	20031113	US 2002157073	20020528
Provisional				US 60-295566	20010605
Provisional				US 60-359843	20020225

Fulltext Word Count: 139761

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/18 (Item 18 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005424213

Derwent Accession: 2003-875896

Pharmaceutical compositions with minicells

Inventor: Berkley, Neil, INV

Klepper, Robert, INV

Sabbadini, Roger, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030207833	A1	20031106	US 2002156811	20020528
Provisional				US 60-359843	20020225

Fulltext Word Count: 140863

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/19 (Item 19 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005416015

Derwent Accession: 2004-069239

Conjugated minicells

Inventor: Surber, Mark, INV

Klepper, Robert, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030203481	A1	20031030	US 2002157213	20020528
Provisional				US 60-359843	20020225

Fulltext Word Count: 139127

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as

diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/20 (Item 20 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005415945

Derwent Accession: 2004-154329
Methods of minicell-based delivery
Inventor: Sabbadini, Roger, INV
Berkley, Neil, INV
Klepper, Robert, INV
Surber, Mark, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030203411	A1	20031030	US 2002156792	20020528
Provisional				US 60-295566	20010605
Provisional				US 60-359843	20020225

Fulltext Word Count: 141451

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/21 (Item 21 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005415471

Derwent Accession: 2003-900614
Minicell-based diagnostics
Inventor: Sabbadini, Roger, INV
Klepper, Robert, INV
Berkley, Neil, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030202937	A1	20031030	US 2002157178	20020528
Provisional				US 60-295566	20010605
Provisional				US 60-359843	20020225

Fulltext Word Count: 139429

Abstract:

The invention provides compositions and methods for the production of

achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

5/3,AB/22 (Item 22 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005407983

Derwent Accession: 2003-852795

Membrane to membrane delivery

Inventor: Surber, Mark, INV

Sabbadini, Roger, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030199089	A1	20031023	US 2002157318	20020528
Provisional				US 60-295566	20010605
Provisional				US 60-359843	20020225

Fulltext Word Count: 141465

Abstract:

The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

5/3,AB/23 (Item 23 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005407982

Derwent Accession: 2003-852794

Minicell-based gene therapy

Inventor: Sabbadini, Roger, INV

Berkley, Neil, INV

Surber, Mark, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030199088	A1	20031023	US 2002156902	20020528
Provisional				US 60-295566	20010605
Provisional				US 60-359843	20020225

Fulltext Word Count: 141280

Abstract:

The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as

diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/24 (Item 24 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005407899

Derwent Accession: 2004-041350

Solid supports with minicells

Inventor: Sabbadini, Roger, INV

Klepper, Robert, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030199005	A1	20031023	US 2002157166	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 139381

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/25 (Item 25 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005407890

Derwent Accession: 2004-080477

Minicell libraries

Inventor: Surber, Mark, INV

Berkley, Neil, INV

Gerhart, William, INV

Sabbadini, Roger, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030198996	A1	20031023	US 2002157147	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-293566	20010524
Provisional				US 60-359843	20020225

Fulltext Word Count: 141320

Abstract:

The invention provides compositions and methods for the production of

achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

5/3,AB/26 (Item 26 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005407889

Derwent Accession: 2004-041349
Forward screening with minicells
Inventor: Sabbadini, Roger, INV
Berkley, Neil, INV
Surber, Mark, INV
Gerhart, William, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030198995	A1	20031023	US 2002156831	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 139346

Abstract:

The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents for
drug discovery.

5/3,AB/27 (Item 27 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005400354

Derwent Accession: 2003-833248
Minicell compositions and methods
Inventor: Surber, Mark, INV
Sabbadini, Roger, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030194798	A1	20031016	US 2002154951	20020524
Provisional				US 60-293566	20010524
Provisional				US 60-359843	20020225

Fulltext Word Count: 141759

Abstract:

The invention provides compositions and methods for the production of

achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

5/3,AB/28 (Item 28 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005400270

Derwent Accession: 2003-844449

Minicell-based transformation

Inventor: Sabbadini, Roger, INV

Berkley, Neil, INV

Surber, Mark, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030194714	A1	20031016	US 2002157299	20020528
Provisional				US 60-295566	20010605
Provisional				US 60-359843	20020225

Fulltext Word Count: 141800

Abstract:

The invention provides compositions and methods for the production of
achromosomal and anucleate cells useful for applications such as
diagnostic and therapeutic uses, as well as research tools and agents
for drug discovery.

5/3,AB/29 (Item 29 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005393451

Derwent Accession: 2003-831632

Minicell-producing parent cells

Inventor: Surber, Mark, INV

Sabbadini, Roger, INV

Segall, Anca, INV

Berkley, Neil, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20030190749	A1	20031009	US 2002157215	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 141420

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/30 (Item 30 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005393385

Derwent Accession: 2003-833248

Minicell-based rational drug design

Inventor: Sabbadini, Roger, INV

Surber, Mark, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030190683	A1	20031009	US 2002157302	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 141102

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/31 (Item 31 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005393303

Derwent Accession: 2003-875310

Target display on minicells

Inventor: Sabbadini, Roger, INV

Berkley, Neil, INV

Surber, Mark, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030190601	A1	20031009	US 2002157096	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 141429

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/32 (Item 32 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005351623

Derwent Accession: 2003-874920

Minicell-based transfection

Inventor: Roger Sabbadini, INV

Neil Berkley, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030166279	A1	20030904	US 2002157391	20020528
Division	PENDING			US 2002154951	20020524
Provisional				US 60-359843	20020225
Provisional				US 60-293566	20010524

Fulltext Word Count: 139641

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/33 (Item 33 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) Format only 2007 Dialog. All rts. reserv.

0005351443

Derwent Accession: 2003-711671

Minicells comprising membrane proteins

Inventor: Roger Sabbadini, INV

Mark Surber, INV

Neil Berkley, INV

Anca Segall, INV

Robert Klepper, INV

Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN
STREET FOURTEENTH FLOOR, IRVINE, CA, 92614, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030166099	A1	20030904	US 2002157305	20020528
Provisional				US 60-295566	20010605
Provisional				US 60-359843	20020225

Fulltext Word Count: 141494

Abstract:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

5/3,AB/34 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rts. reserv.

12338834 Genuine Article#: 755KU Number of References: 95
Title: Diagnosis of militarily relevant diseases using oral fluid and saliva antibodies: Fluorescence polarization immunoassay (ABSTRACT AVAILABLE)
Author(s): Ragain JC; Cullum ME (REPRINT) ; Lininger LA; Schade SZ; Cope SE ; Simonson LG
Corporate Source: USN,Inst Dent & Biomed Res, Dept Appl Lab Sci,310A B-St,Bldg 1-H/Great Lakes//IL/60088 (REPRINT); USN,Inst Dent & Biomed Res, Dept Appl Lab Sci,Great Lakes//IL/60088
Journal: MILITARY MEDICINE, 2003, V168, N11 (NOV), P915-921
ISSN: 0026-4075 Publication date: 20031100
Publisher: ASSN MILITARY SURG US, 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA

Language: English Document Type: ARTICLE

Abstract: This laboratory is developing fluorescence polarization (FP) methods as diagnostic tools to assay antibodies in saliva and other oral fluids. FP provides quantitation of molecular interaction, such as antigen-antibody binding, of a single, small-volume sample in real time and without prior separation of components such as blood cells. There is potential for widespread use of these homogeneous assays as noninvasive tests, especially as more compact, simplified fluorescence polarimeters become available. FP tests can be designed that are applicable to a wide spectrum of microorganisms and may be used in a clinic or far-forward deployed setting to aid in diagnosis of disease or verification of vaccination. Rapid salivary diagnostics, including FP, have been identified by the Office of Naval Research as requirements for future naval capabilities in basic and applied medical research for warfighter protection in casualty prevention. The applications of FP salivary diagnostics for determination of tuberculosis exposure and of anthrax immunization status are discussed as examples.

NOV
03
after
primary

5/3,AB/35 (Item 1 from file: 440)
DIALOG(R)File 440:Current Contents Search(R)
(c) 2007 The Thomson Corp. All rts. reserv.

21419672 Document Delivery Available: 0002309507
PUBLICATION: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005
ISSN: 0066-4804

5/3,AB/36 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2007 WIPO/Thomson. All rts. reserv.

01248439
FLUORESCENCE POLARIZATION INSTRUMENTS AND METHODS FOR DETECTION
OF EXPOSURE TO BIOLOGICAL MATERIALS BY FLUORESCENCE
POLARIZATION IMMUNOASSAY OF SALIVA, ORAL OR BODILY FLUIDS

INSTRUMENTS ET PROCEDES DE POLARISATION DE FLUORESCENCE POUR LA DETECTION D'EXPOSITION AUX MATIERES VIVANTES PAR LE DOSAGE IMMUNOLOGIQUE PAR LA POLARISATION DE FLUORESCENCE DE LA SALIVE, DE LIQUIDES BUCCAUX OU ORGANIQUES

Patent Applicant/Assignee:

THE UNITED STATES OF AMERICA as represented by The Secretary of the Navy
Naval Medical Research Center, Code 00L, 503 Robert Grant Avenue,
Silver Spring, MD 20920, US, US (Residence), US (Nationality)

Inventor(s):

CULLUM Malford E, GRAYSLAKE, IL, US,
SIMONSON Lloyd G, 11204 Michigan Drive, Spring Grove, IL 60081, US,
SCHADE Sylvia Z, 189 Delaphaine Road, Riverside, IL 60546, US,
LININGER Linda Z, GRAYSLAKE, IL, US,
PEDERSON Ernest, 24909 Fox Trail W., Lake Villa, IL 60040, US,

Legal Representative:

THE UNITED STATES OF AMERICA as represented by The Secretary of the Navy
Naval Medical Research Center (agent), Code 00L, 503 Robert Grant
Avenue, Silver Spring, MD 20920, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200554854 A1 20050616 (WO 0554854)
Application: WO 2003US32736 20031105 (PCT/WO US03032736)
Priority Application: WO 2003US32736 20031105

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK
SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE
SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 11661

English Abstract

The inventive subject matter relates to a method for detecting the presence of a biological substance of interest in a test sample of saliva or oral fluid, comprising combining said test sample with a fluorescence labeled ligand to said biological substance and detecting a change in the fluorescence polarization of said test sample produced by binding of said fluorescence-labeled ligand to said biological substance. In one aspect of the inventive subject matter, said method comprises additional steps for comparing the fluorescence polarization of said test sample with the fluorescence polarization of a control solution. Also provided is a miniaturized, portable apparatus for measuring the ***fluorescence*** ***polarization*** of a liquid sample.

French Abstract

La presente invention a trait a un procede pour la detection de la presence d'une substance biologique d'interet dans un echantillon d'essai de la salive ou de liquide buccal, comprenant la combinaison dudit echantillon d'essai avec un ligand marque par fluorescence a ladite substance biologique et la detection d'une modification dans la polarisation de fluorescence dudit echantillon d'essai produite par la liaison dudit ligand marque par fluorescence a ladite substance biologique. Dans un aspect de l'invention, ledit procede comprend des etapes additionnelles pour la comparaison de la polarisation de fluorescence dudit echantillon d'essai avec la polarisation de fluorescence d'une solution temoin. L'invention a egalement trait a un appareil portatif miniaturise pour la mesure de la polarisation de

fluorescence d'un echantillon liquide.

5/3,AB/37 (Item 2 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2007 WIPO/Thomson. All rts. reserv.

01210946

SYSTEM FOR DETECTING POLYNUCLEOTIDES
SYSTEME DE DETECTION DE POLYNUCLEOTIDES

Patent Applicant/Assignee:

INVESTIGEN INC, 750 Alfred Nobel Drive, Hercules, CA 94547, US, US
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

KOSHINSKY Heather, 2033 Carquinez Avenue, El Cerrito, CA 94530, US, US
(Residence), CA (Nationality), (Designated only for: US)

ZWICK Michael S, 6986 Gibson Canyon Road, Vacaville, CA 95688, US, US
(Residence), US (Nationality), (Designated only for: US)

CHOI K Yeon, 3221 Briggs Avenue, Apartment E, Alameda, CA 94501, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

WORRALL Timothy A et al (agent), Morrison & Foerster, LLP., 425 Market
Street, San Francisco, CA 94105, US

Patent and Priority Information (Country, Number, Date):

Patent: WO 200517181 A2-A3 20050224 (WO 0517181)

Application: WO 2004US16118 20040520 (PCT/WO US2004016118)

Priority Application: US 2003471827 20030520

Designated States:

(All protection types applied unless otherwise stated - for applications
2004+)

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM
DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO
RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO
SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 44174

English Abstract

The present invention relates to methods for detecting the presence or amount of a target polynucleotide. A polynucleotide, target nucleic acid analog, and dye are combined to form a mixture. The optical property of the dye is compared to a reference value characteristics of the rate of change in the optical property of the dye in a similar mixture containing a known amount of a target polynucleotide/nucleic acid analog hybrid to determine a relative rate of change in the optical property. The relative rate of change in the optical property of dye in the mixture is correlated with the presence or amount of the specified target polynucleotide in the sample.

French Abstract

La presente invention concerne des procedes permettant de detecter la presence ou la concentration d'un polynucleotide cible. Dans ces procedes, un polynucleotide, un analogue d'acide nucleique cible et un colorant sont combines pour former un melange. Ces procedes consistent ensuite a comparer la propriete optique du colorant a une valeur de reference caracteristique du taux de variation de la propriete optique du colorant dans un melange similaire contenant une concentration connue d'un hybride polynucleotide/analogue d'acide nucleique cible pour

determiner un taux de variation relatif de la propriete optique. Ce taux de variation relatif de la propriete optique du colorant dans le melange est associe a la presence ou a la concentration du polynucleotide cible specifie dans l'echantillon.

5/3,AB/38 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2007 WIPO/Thomson. All rts. reserv.

01196513

ANTHRAX ANTIGEN VACCINE CULTURES BY FLUORESCENCE POLARIZATION
ESSAI IMMUNOLOGIQUE RAPIDE D'ANTIGENE PROTECTEUR CONTRE L'ANTHRAX DANS DES
CULTURES VACCINALES PAR POLARISATION A FLUORESCENCE

Patent Applicant/Assignee:

THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY
NAVAL MEDICAL RESEARCH CENTER CODE 00L, 503 Robert Grant Avenue, Silver
Spring, MD 20920, US, US (Residence), US (Nationality), (For all
designated states except: US)

Inventor(s):

CULLUM Malford E, 440 Wicks Street, Grayslake, IL, US,
HINE Paul M, 160 Fawn Creek Drive, Holt, MI 48842, US,
SIMONSON Lloyd G, 11204 Michigan Drive, Spring Grove, IL 60081, US,
SHIH Chun N, 825 Crown Boulevard, East Lansing, MI 48823, US,
BIENEK Diane R, 608 Deerpath Drive, Lindenhurst, IL 60046, US,
PARK Sukjoon, 2916 Marfitt Road, East Lansing, MD 4882, US,
RAGAIN James C Jr, 2711 Perry Street, Great Lakes, IL 60088, US,

Legal Representative:

HEMBY Joseph K Jr (et al) (agent), Naval Medical Research Center, Code
00L, 503 Robert Grant Avenue, Silver Spring, MD 20920, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200503376 A2-A3 20050113 (WO 0503376)
Application: WO 2004US9386 20040326 (PCT/WO US04009386)
Priority Application: US 2003457940 20030328

Designated States:

(All protection types applied unless otherwise stated - for applications
2004+)

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM
DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO
RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO
SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 7702

English Abstract

The inventive subject matter relates to a competitive method for
estimating the concentration in a sample of a Bacillus
anthracis protein or antibody thereof selected from the group
consisting of protective antigen (PA), lethal factor (LF) and
edema factor (EF). The method may employ the use of ***Fluorescence***
Polarization, FLT or FRET. The competitive methods are capable of
detecting a target protein within 5 minutes within the range of 0.1 to
10.0 nM. The methods provide for the rapid detection and quantitation of
bacteria, bacterial antigen or antibody in culture media or broth of
growing cultures of bacteria, including B. anthracis by fluorescent
methods.

French Abstract

L'invention porte sur un procede competitif d'estimation de la concentration dans un echantillon d'une proteine d'un bacille du charbon ou de son anticorps selectionne(e) dans le groupe constitue d'un antigene protecteur PA d'un facteur letal LF et d'un facteur oedeme EF. Le procede peut tirer profit de l'utilisation de la polarisation a fluorescence (FLT ou FRET). Les procedes competitifs sont aptes a detecter une proteine cible en 2 minutes dans une fourchette allant de 0,1 a 10,0 nM. Les procedes assurent la detection rapide et la quantification de bacteries, d'un antigene bacterien ou d'un anticorps dans un milieu de culture ou un milieu liquide de croissance de cultures de bacteries, y compris le bacille du charbon au moyen de procedes fluorescents.

5/3,AB/39 (Item 4 from file: 349)
DIALOG(R)File 349:PCT.FULLTEXT
(c) 2007 WIPO/Thomson. All rts. reserv.

01164075

NUCLEIC ACID LIGAND TO B. ANTHRACIS ***PROTECTIVE*** ***ANTIGEN***
LIGANDS D'ACIDE NUCLEIQUE POUR DES ANTIGENES PROTEGEANT CONTRE B. ANTHRACIS
Patent Applicant/Assignee:

ARCHEMIX CORP, One Hampshire Street, Cambridge, MA 02139, US, US
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

WILSON Chareles, 229 Lexington Road, Concord, MA 01742, US, US

(Residence), US (Nationality), (Designated only for: US)

EPSTEIN David, 56 Pine Street, Belmont, MA 02478, US, US (Residence), US

(Nationality), (Designated only for: US)

CLOAD Sharon T, 7 Granville Road, Cambridge, MA 02138, US, US (Residence)

, US (Nationality), (Designated only for: US)

MARSH Nicholas, 103 Marlborough Street, Apt. 7, Boston, MA 02116, US, US

(Residence), AU (Nationality), (Designated only for: US)

HAMAGUCHI Nobuko, 7 Dartmouth Drive, Framingham, MA 01701, US, US

(Residence), JP (Nationality), (Designated only for: US)

Legal Representative:

ELRIFI Ivor R (agent), Mintz, Levin, Cohn, Ferris,, Glosky and Popeo,

P.C., One Financial Center, Boston, MA 02111, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200485665 A2-A3 20041007 (WO 0485665)

Application: WO 2003US20844 20030619 (PCT/WO US03020844)

Priority Application: US 2002390214 20020619; US 2003445977 20030207; US

2003453259 20030310; US 2003492930 20030415

Parent Application/Grant:

Related by Continuation to: US 2002390214 20020619 (CIP); US 2003445977

20030207 (CIP); US 2003453259 20030310 (CIP); US 2003492930 20030415

(CIP)

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ

EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR

LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE

SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE

SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 43589

English Abstract

Materials and methods are provided to treat subjects exposed to

bacillus anthracis protective antigen to prevent
virulence of anthrax disease caused by ***bacillus*** ***anthracis***
Materials and methods are also provided to detect the presence of
bacillus anthracis protective antigen in a
sample.

French Abstract

Matieres et methodes destinees au traitement de sujets exposes a
l'antigene protecteur contre Bacillus anthracis pour empecher
la virulence du charbon cause par ***Bacillus*** ***anthracis*** . Des
matieres et des methodes permettant de detecter la presence de l'antigene
protecteur contre Bacillus anthracis dans un echantillon sont
egalement decrites.

5/3,AB/40 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2007 WIPO/Thomson. All rts. reserv.

01137240

HIGH-SENSITIVITY ASSAYS FOR PATHOGEN DETECTION USING METAL-ENHANCED
FLUORESCENCE

DOSAGE BIOLOGIQUE GRANDE SENSIBILITE PERMETTANT DE DETECTER DES PATHOGENES
PAR FLUORESCENCE AMELIOREE PAR METAL

Patent Applicant/Assignee:

UNIVERSITY OF MARYLAND BIOTECHNOLOGY, Institute Off. Of Research
Admin./Tech. Dev., 701 E. Pratt Street, Suite 200, Baltimore, MD 21202,
US, US (Residence), US (Nationality), (For all designated states
except: US)

Patent Applicant/Inventor:

GEDDES Chris D, 15 Charles Plaza, Apartment 805, Baltimore, MD 21201, US,
US (Residence), GB (Nationality), (Designated only for: US)
LAKOWICZ Joseph R, 10037 Fox Den Road, Ellicott City, MD 21046, US, US
(Residence), US (Nationality), (Designated only for: US)
BAILLIE Les, 7356 Eden Brook Drive, Apartment 715, Columbia, MD 21046, US
, US (Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

FUIERER Marianne (et al) (agent), Intellectual Property/Technology Law,
P.O. Box 14329, Research Triangle Park, NC 27709, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200459279 A2-A3 20040715 (WO 0459279)
Application: WO 2003US38163 20031126 (PCT/WO US03038163)
Priority Application: US 2002429263 20021126

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE
SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE
SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 15361

English Abstract

The present invention relates to an assay including a surface having
silver colloids or islands attached thereto. Attached to the surface
and/or silver colloids/islands are polynucleotides which are
complimentary to a target polynucleotide sequence. The assay is performed

by adding the target polynucleotide sequence to the assay surface and allowed to hybridize with the capture polynucleotides. Fluorophore-labeled capture polynucleotides are added and hybridize to the target polynucleotide. Bound target polynucleotides are detected by metal enhanced fluorescence.

French Abstract

L'invention concerne un dosage biologique comprenant une surface dotée d'îlots ou colloïdes d'argent reliés. Des polynucleotides sont fixés à la surface et/ou aux îlots/colloïdes d'argent, lesquels polynucleotides sont complémentaires d'une séquence polynucleotidique cible. Le dosage biologique décrit dans cette invention est réalisé par ajout de la séquence polynucleotidique cible à la surface du dosage biologique; ledit dosage s'hybride avec les polynucleotides captures. Les polynucleotides captures marqués par fluorophores sont ajoutés et hybridés à la polynucleotide cible. Les polynucleotides cibles liés sont détectés par fluorescence améliorée par métal.

5/3,AB/41 (Item 6 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2007 WIPO/Thomson. All rts. reserv.

01043122

REAGENTS AND METHODS FOR ASSAYING BACILLUS ANTHRACIS LETHAL
FACTOR PROTEASE

REACTIFS ET PROCÉDES POUR DES DOSAGES DES PROTÉASES DE FACTEUR LÉTHAL DU <I>
BACILLUS ANTHRACIS</I>

Patent Applicant/Assignee:

MERCK & CO INC, 126 East Lincoln Avenue, Rahway, NJ 07065-0907, US, US
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

CUNNINGHAM Barry R, 126 East Lincoln Avenue, Rahway, NJ 07065-0907, US,
US (Residence), US (Nationality), (Designated only for: US)

CUMMINGS Richard T, 126 East Lincoln Avenue, Rahway, NJ 07065-0907, US,
US (Residence), US (Nationality), (Designated only for: US)

HERMES Jeffrey D, 126 East Lincoln Avenue, Rahway, NJ 07065-0907, US, US
(Residence), US (Nationality), (Designated only for: US)

SALOWE Scott P, 126 East Lincoln Avenue, Rahway, NJ 07065-0907, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

MERCK & CO INC (commercial rep.), 126 East Lincoln Avenue, Rahway, NJ
07065-0907, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200373066 A2-A3 20030904 (WO 0373066)

Application: WO 2003US5553 20030221 (PCT/WO US03005553)

Priority Application: US 2002359707 20020225

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

CA JP US

(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI
SK TR

Publication Language: English

Filing Language: English

Fulltext Word Count: 5788

English Abstract

The present invention features *Bacillus anthracis* lethal factor substrate and assays employing the substrate to measure lethal factor activity and to screen for compounds affecting lethal factor activity (Figure 1). Preferred substrates contain one or more detectable labels and have a sufficiently high turnover rate to be suitable for use in a high throughput screen.

French Abstract

L'invention concerne un substrat de facteur letal du bacillus anthracis et des dosages utilisant ledit substrat pour mesurer l'activite du facteur letal et pour cribler les composes affectant l'activite du facteur letal. Des substrats preferes contiennent un ou plusieurs marqueurs detectables et presentent un taux de rotation suffisamment eleve de maniere a etre utilises dans un criblage a debit eleve.

5/3,AB/42 (Item 7 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2007 WIPO/Thomson. All rts. reserv.

01042425

MINICELL COMPOSITIONS AND METHODS

COMPOSITIONS MINICELLULAIRES ET METHODES ASSOCIEES

Patent Applicant/Assignee:

MPEX BIOSCIENCE INC, 5500 Campanile Drive, San Diego, CA 92182-4614, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

SABBADINI Roger A, 12509 Del Sol Road, Lakeside, CA 92040, US, US
(Residence), US (Nationality), (Designated only for: US)
SURBER Mark, Apt. A, 344 "G" Avenue, Coronado, CA 92118, US, US
(Residence), US (Nationality), (Designated only for: US)
BERKLEY Neil, 3226 Erie Street, San Diego, CA 92117, US, US (Residence),
US (Nationality), (Designated only for: US)
SEGALL Anca, 1911 33rd Street, San Diego, CA 92102, US, US (Residence),
US (Nationality), (Designated only for: US)
KLEPPER Robert, 12828 War Horse Street, San Diego, CA 92129, US, US
(Residence), US (Nationality), (Designated only for: US)
GIACALONE Matthew, 4121 Udall Street #2, San Diego, CA 92107, US, US
(Residence), US (Nationality), (Designated only for: US)
GERHART William, 4324 Resmar Road, La Mesa, CA 91941, US, US (Residence),
US (Nationality), (Designated only for: US)

Legal Representative:

HUNT Dale C (agent), Knobbe, Martens, Olson & Bear, LLP, 14th Floor, 2040
Main Street, Irvine, CA 92614, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200372014 A2-A3 20030904 (WO 0372014)
Application: WO 2002US16877 20020528 (PCT/WO US02016877)
Priority Application: US 2002359843 20020225; US 2002154951 20020524

Parent Application/Grant:

Related by Continuation to: US 2002154951 20020524 (CIP); US 2002359843
20020225 (CIP)

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 155429

English Abstract

The invention provides compositions and methods for the production of

achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

French Abstract

L'invention concerne des compositions et des methodes permettant de produire des cellules achromosomiques et anucleees convenant a des applications diagnostiques et therapeutiques ainsi qu'a des outils de recherche et a des agents destines a la recherche medicamenteuse.

5/3,AB/43 (Item 8 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2007 WIPO/Thomson. All rts. reserv.

00960163

NOVEL ANTIGEN BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL, AND AGRICULTURAL APPLICATIONS, AND METHODS FOR GENERATING AND SCREENING THEREOF

NOUVELLES MOLECULES DE LIAISON A UN ANTIGENE DESTINEES A DES APPLICATIONS THERAPEUTIQUES, DIAGNOSTIQUES, PROPHYLACTIQUES, ENZYMATIQUES, INDUSTRIELLES ET AGRICOLES ET PROCEDES DE GENERATION ET DE CRIBLAGE DE TELLES MOLECULES

Patent Applicant/Assignee:

DIVERSA CORPORATION, 4955 Directors Place, San Diego, CA 92121, US, US
(Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

SHORT Jay M, P.O. Box 7214, Rancho Santa Fe, CA 92067-7214, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

EINHORN Gregory P (agent), Fish & Richardson P.C., 4350 La Jolla Village Drive, Suite 500, San Diego, CA 92122, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200292780 A2-A3 20021121 (WO 0292780)

Application: WO 2002US15767 20020517 (PCT/WO US02015767)

Priority Application: US 2001300381 20010517; US 2001300907 20010625

Parent Application/Grant:

Related by Continuation to: US 2001300907 20010625 (CIP); US 2001300381 20010517 (CIP)

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 202338

English Abstract

The invention is directed to methods for generating sets, or libraries, of nucleic acids encoding antigen-binding sites, such as antibodies, antibody domains or other fragments, including single and double stranded antibodies, major histocompatibility complex (MHC) molecules, T cell receptors (TCRs), and the like. This invention provides methods for generating variant antigen binding sites, e.g., antibodies and specific domains or fragments of antibodies (e.g., Fab or Fc domains), by altering template nucleic acids including by saturation mutagenesis, synthetic ligation reassembly, or a combination thereof. In one aspect, the

invention provides methods for generating all human or humanized antibodies and evolving them to achieve optimized properties related to stability, duration, expression, production, enzymatic activity, affinity, avidity, localization, and other immunological properties. Polypeptides generated by these methods can be analyzed using a novel capillary array platform, which provides unprecedented ultra-high throughput screening.

French Abstract

La presente invention se rapporte a des procedes permettant de generer des ensembles, ou banques, d'acides nucleiques codant des sites de liaison a un antigene, tels que des anticorps, des domaines d'anticorps ou autres fragments, y compris des anticorps a brin simple ou double, du complexe majeur d'histocompatibilite (CMH), des recepteurs des lymphocytes (TCR), et analogues. Cette invention se rapporte a des procedes permettant de generer des sites de liaison a un antigene variant, par exemple des anticorps et des domaines ou des fragments specifiques d'anticorps (par exemple, les domaines Fab ou Fc), par modification d'acides nucleiques matrices et notamment par mutagenese a saturation, par reassemblage avec ligature synthetique ou par une combinaison de ces procedes. Dans un mode de realisation, l'invention se rapporte a des procedes permettant de generer tous les anticorps humains ou humanises et de les developper de maniere a obtenir des proprietes optimisees s'agissant de stabilite, duree, expression, production, activite enzymatique, affinite, avidite, localisation et autres proprietes immunologiques. Ces procedes permettent de generer des polypeptides qui peuvent etre analyses au moyen d'une nouvelle plate-forme a reseau capillaire, qui permet un criblage a rendement extremement eleve et sans precedent.

5/3,AB/44 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

142019550 CA: 142(2)19550b PATENT
Rapid competitive fluorescence-polarization immunoassay of anthrax protective antigen in vaccine cultures and bodily fluids
INVENTOR(AUTHOR): Cullum, Malford E.; Hine, Paul; Simonson, Lloyd G.; Shih, Chun N.; Bienek, Diane R.; Park, Sukjoon; Ragain, James C.
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20040235075 A1 DATE: 20041125
APPLICATION: US 2004809877 (20040326) *US 2003PV457940 (20030328)
PAGES: 10 pp. CODEN: USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435007320; G01N-033/554A; G01N-033/569B

5/3,AB/45 (Item 1 from file: 390)
DIALOG(R)File 390:Beilstein Database - Facts
(c) 2007 Beilstein GmbH. All rts. reserv.

78623

Synonym: cyclo- lin -hepta alpha 1-)4 - D -glucopyranosyl; Cyclo- lin -hepta 1 alpha =>4 -D-glucopyranosyl; Cycloheptapentylose; beta -cyclodextrin; beta-cyclodextrin hydrate; cycloheptaamylose
CAS RN: 7585-39-9*, 130322-66-6, 130322-68-8
Molecular Formula: C42H70O35
Number of fragments: 1
Molecular Wt: 1134.99
Lawson Nbr: 24053
Compound Type: heterocyclic
Structure Characteristics:
Stereo Compound

Total No. of Rings: 8

Cross File Reference

Description: beta -Cyclodextrin, for biochemistry Available:

E.Merck, Darmstadt External Access Id: 2127

Description: beta-Cyclodextrin, purum 99 percent (HPLC) Available:

Fluka External Access Id: 28707

Description: cycloheptapentylose Available: EINECS External Access Id: 231-493-2

Description: BETA-CYCLODEXTRIN HYDRATE Available: Aldrich External Access Id: 856088

Structure Keywords: Stereo compound

Similar Stereo Compounds: Constitution Id (CI=): 88779

Similar Tautomer Compounds: Tautomer Id (BT=): 95189

No. Ref: 1015

Data Present:

Data	Refs	Data Type
	1	SD Constitutional Data
	1	PR Preparative Data
	3867	PP Physical Properties
	75	PE Pharmacological, Ecological, and Use Data
	39	DR Derivative
	1	KW Further Information

Preparative Data

Purification Method

(Ref. 4)

Refs.

4, 3375580 Koesteret al JLACBF Justus Liebigs Ann. Chem.
(1975)752,784

5/3,AB/46 (Item 1 from file: 340)

DIALOG(R)File 340:CLAIMS(R)/US Patent

(c) 2007 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10856885 IFI Acc No: 2005-0095601

IFI Publication Control No: 2005-0095601 IFI Chemical Acc No: 2005-0022091

Document Type: C

FLUORESCENCE POLARIZATION INSTRUMENTS AND METHODS FOR DETECTION

OF EXPOSURE TO BIOLOGICAL MATERIALS BY FLUORESCENCE

POLARIZATION IMMUNOASSAY OF SALIVA, ORAL OR BODILY FLUIDS

Inventors: Cullum Malford E (US); Lininger Linda A (US); McArthur Alan L
(US); Schade Sylvia Z (US); Simonson Lloyd G (US)

Assignee: Unassigned Or Assigned To Individual

Assignee Code: 68000

Attorney, Agent or Firm: NAVAL MEDICAL RESEARCH CENTER;Office of Counsel

(Code 00L), 503 Robert Grant Avenue, Silver Spring, MD, 20910-7500, US

Publication (No,Kind,Date), Applic (No,Date):

US 20050095601 A1 20050505 US 2003700868 20031105

Priority Applic(No,Date): US 2003700868 20031105

Abstract: The inventive subject matter relates to a method for detecting the presence of a biological substance of interest in a test sample of saliva or oral fluid, comprising combining said test sample with a fluorescence-labeled ligand to said biological substance and detecting a change in the fluorescence polarization of said test sample produced by binding of said fluorescence-labeled ligand to said biological substance. In one aspect of the inventive subject matter, said method comprises additional steps for comparing the fluorescence polarization of said test sample with the fluorescence

polarization of a control solution. Also provided is a miniaturized, portable apparatus for measuring the fluorescence polarization of a liquid sample.

5/3,AB/47 (Item 2 from file: 340)
DIALOG(R)File 340:CLAIMS(R)/US Patent
(c) 2007 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10727825 IFI Acc No: 2004-0235075
IFI Publication Control No: 2004-0235075 IFI Chemical Acc No: 2004-0064853
Document Type: C
RAPID IMMUNOASSAY OF ANTHRAX PROTECTIVE ANTIGEN IN VACCINE
CULTURES AND BODILY FLUIDS BY FLUORESCENCE POLARIZATION; USING
COMPETITIVE IMMUNOGLOBULIN BINDING AND FLUORESCENT POLARIZATION TO
IDENTIFY AND QUANTIFY CONCENTRATIONS OF BACILLUS PROTECTIVE
ANTIGEN, LETHAL FACTOR AND EDEMA FACTOR IN BODILY FLUIDS
Inventors: Bienek Diane R (US); Cullum Malford E (US); Hine Paul (US); Park
Sukjoon (US); Ragain James C JR (US); Shih Chun N (US); Simonson Lloyd
G (US)
Assignee: Unassigned Or Assigned To Individual
Assignee Code: 68000
Attorney, Agent or Firm: NAVAL MEDICAL RESEARCH CENTER;ATTN: (CODE 00L),
503 ROBERT GRANT AVENUE, SILVER SPRING, MD, 20910-7500, US
Publication (No,Kind,Date), Applic (No,Date):
US 20040235075 A1 20041125 US 2004809877 20040326
Priority Applic(No,Date): US 2004809877 20040326
Provisional Applic(No,Date): US 60-457940 20030328

Abstract: The inventive subject matter relates to a competitive method for
estimating the concentration in a sample of a Bacillus
anthracis protein or antibody thereof selected from the group
consisting of protective antigen (PA), lethal factor (LF) and
edema factor (EF). The method may employ the use of ***Fluorescence***
Polarization, FLT or FRET. The competitive methods are capable of
detecting a target protein within 5 minutes within the range of 0.1 to 10.0
nM. The methods provide for the rapid detection and quantitation of
bacteria, bacterial antigen or antibody in culture media or broth of
growing cultures of bacteria, including B. anthracis by fluorescent
methods.

5/3,AB/48 (Item 1 from file: 345)
DIALOG(R)File 345:Inpadoc/Fam.& Legal Stat
(c) 2007 EPO. All rts. reserv.

61564431 Family ID: 31564432
<No. of Patents: 5> <No. of Countries: 2>
<No. of Legal Status: 13>
Patent Basic (No,Kind,Date): US 20040235075 A1 20041125
Rapid immunoassay of anthrax protective antigen in vaccine cultures and
bodily fluids by fluorescence polarization (English)

Author (Inventor): CULLUM MALFORD E (US); HINE PAUL (US); SIMONSON LLOYD
G (US); SHIH CHUN N (US); BIENEK DIANE R (US); PARK SUKJOON (US);
RAGAIN JAMES C (US)
Record Type: Legal Status; Abstract; Cited Refs

Patent Family:

Patent No	Kd Date	Applic No	Kd Date	Wk Added
US 20040235075	A1 20041125	US 2004809877	A 20040326	200449 (B)
US 20050164168	A1 20050728	US 2004855325	A 20040528	200532
WO 2005003376	A2 20050113	WO 2004US9386	A 20040326	200504
WO 2005003376	A3 20050818	WO 2004US9386	A 20040326	200535
WO 2005118884	A1 20051215	WO 2004US16880	A 20040528	200551

Priority Data (No,Kind,Date):
US 2003457940 P 20030328
US 2004809877 A 20040326

applicant

Abstracts:

- US 20040235075 A1 20041125 (English) The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a *Bacillus anthracis* protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of ***Fluorescence*** ***Polarization***, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0.1 to 10.0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including *B. anthracis* by fluorescent methods.
- US 20050164168 A1 20050728 (English) The inventive subject matter relates to a competitive method for the diagnosis of latent infectious disease, such as *Mycobacterium tuberculosis*, by estimating, the concentration of cytokine, such as interferon-gamma produced by stimulated immune cells, collected from whole blood, by Fluorescence Polarization (FP), Fluorescence Resonance Energy Transfer (FRET) or Fluorescence Lifetime (FLT) due to antibody-cytokine interaction or by dimerization of the cytokine.
- WO 2005003376 A2 20050113 (English) The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a *Bacillus anthracis* protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of ***Fluorescence*** ***Polarization***, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0.1 to 10.0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including *B. anthracis* by fluorescent methods.
- WO 2005003376 A2 20050113 (French) L'invention porte sur un procede competitiv d'estimation de la concentration dans un echantillon d'une proteine d'un bacille du charbon ou de son anticorps selectionne(e) dans le groupe constitue d'un antigene protecteur PA d'un facteur letal LF et d'un facteur oedeme EF. Le procede peut tirer profit de l'utilisation de la polarisation a fluorescence (FLT ou FRET). Les procedes competitifs sont aptes a detecter une proteine cible en 2 minutes dans une fourchette allant de 0,1 a 10,0 nM. Les procedes assurent la detection rapide et la quantification de bacteries, d'un antigene bacterien ou d'un anticorps dans un milieu de culture ou un milieu liquide de croissance de cultures de bacteries, y compris le bacille du charbon au moyen de procedes fluorescents.
- WO 2005003376 A3 20050818 (English) The inventive subject matter relates to a competitive method for estimating the concentration in a sample of a *Bacillus anthracis* protein or antibody thereof selected from the group consisting of protective antigen (PA), lethal factor (LF) and edema factor (EF). The method may employ the use of ***Fluorescence*** ***Polarization***, FLT or FRET. The competitive methods are capable of detecting a target protein within 5 minutes within the range of 0.1 to 10.0 nM. The methods provide for the rapid detection and quantitation of bacteria, bacterial antigen or antibody in culture media or broth of growing cultures of bacteria, including *B. anthracis* by fluorescent methods.
- WO 2005003376 A3 20050818 (French) L'invention porte sur un procede competitiv d'estimation de la concentration dans un echantillon d'une proteine d'un bacille du charbon ou de son anticorps selectionne(e) dans le groupe constitue d'un antigene protecteur PA d'un facteur letal LF et d'un facteur oedeme EF. Le procede peut tirer profit de l'utilisation de la polarisation a fluorescence (FLT ou FRET). Les procedes competitifs sont aptes a detecter une proteine cible en 2 minutes dans une fourchette allant de 0,1 a 10,0 nM. Les procedes

assurent la detection rapide et la quantification de bacteries, d'un antigene bacterien ou d'un anticorps dans un milieu de culture ou un milieu liquide de croissance de cultures de bacteries, y compris le bacille du charbon au moyen de procedes fluorescents.

WO 2005118884 A1 20051215 (English) The inventive subject matter relates to a competitive method for the diagnosis of latent infectious disease, such as Mycobacterium tuberculosis, by estimating, the concentration of cytokine, such as interferon-gamma produced by stimulated immune 5 cells, collected from whole blood, by Fluorescence Polarization (FP), Fluorescence Resonance Energy Transfer (FRET) or Fluorescence Lifetime (FLT) due to antibodycytokine interaction or by dimerization of the cytokine.

WO 2005118884 A1 20051215 (French) L'invention concerne un procede competitif permettant de diagnostiquer une maladie infectieuse latente, telle que Mycobacterium tuberculosis, qui consiste a estimer la concentration de la cytokine, par exemple l'interferon gamma produit par des cellules immunes stimulees, prelevees dans le sang entier par polarisation de fluorescence (FP), par transfert d'energie de resonance de fluorescence (FRET) ou par duree de vie de fluorescence (FLT) du fait de l'interaction anticorps-cytokine ou par dimerisation de la cytokine.

?